Given the financial status of the UK, one of the only arenas that has experienced growth is the Biotech market and it has been shown that investment in Biotech, gives much higher returns that other sectors. However this needs to stay as a focus as if the UK does not continue to invest and concentrate on new products, we risk this strong position. Continued development in UK innovation and NHS involvement with UK companies should be seen as a win-win situation and needs to be given increased focus and drive from all levels. The UK seems to get bogged down in red tape for implementing products and services that may make total common sense. All parties need to look at ways in which these can be used as they may increase patient outcomes and therefore overall costs in the long run. There are obviously areas in which we need stringent Regulation but there are also areas where if the product does not need to be regulated so thoroughly.